Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: SB 202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38 alpha (SAPK2A, MAPK14) and p38 beta (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively. When tested at 10 µM, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs). Pyridinyl imidazole inhibitors, including this compound, directly bind p38 MAP kinases in the ATP binding pocket. Recently, SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder.
SB 202190 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 202190 in the solvent of choice. SB 202190 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of SB 202190 in these solvents is approximately 0.25, 16, and 10 mg/ml, respectively. SB 202190 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 202190 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SB 202190 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Jiang, Y., Chen, C., Li, Z., et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J. Biol. Chem. 271(30), 17920-17926 (1996).
Davies, S.P., Reddy, H., Caivano, M., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
Fox, T., Coll, J.T., Xie, X., et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7, 2249-2255 (1998).
Fu, X., Lawson, M.A., Kelley, K.W., et al. HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J. Neuroinflammation 8(88), 1-12 (2011).
Riis, J.L., Johansen, C., Vestergaard, C., et al. CCL27 expression is regulated by both p38 MAPK and IKKβ signalling pathways. Cytokine 56(3), 699-707 (2011).